Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai Municipality, China13 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, endocrine system disorder, malignant endocrine neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm | Recruiting | Phase 2 / Phase 3 | 2026-09-17 | NCT06361888 | |
| Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/Obesity | Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nutritional disorder, obesity disorder, overnutrition | Recruiting | Phase 3 | 2026-05-27 | NCT07469800 | |
| Finerenone in Patients Undergoing Transcatheter Aortic Valve Implantation With Heart Failure | Finerenone; HFpEF - Heart Failure With Preserved Ejection Fraction; TAVI(Transcatheter Aortic Valve Implantation) | Not yet recruiting | Phase 3 | 2026-05-08 | NCT07575672 | |
| A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors | Locally Advanced Unresectable or Metastatic Solid Tumors | Recruiting | Phase 1 | 2026-05-04 | NCT05458219 | |
| Trial of CS060380 Tablets for Non-alcoholic Steatohepatitis (NASH) | metabolic dysfunction-associated steatohepatitis | Recruiting | Phase 2 | 2026-03-13 | NCT07198386 | |
| To Evaluate the Efficacy and Safety of KN060 in Essential Hypertension | cardiovascular disorder, essential hypertension, hypertensive disorder, vascular disorder | Recruiting | Phase 1 | 2025-09-25 | NCT07191899 | |
| Efficacy and Safety of VAH as a Bridging Regimen to Allo-HCT in Relapsed/Refractory AML | Relapse Leukemia | Not yet recruiting | Phase 2 | 2025-07-29 | NCT07091006 | |
| Reduced Intensity Conditioning for MDS | myelodysplastic syndrome | Not yet recruiting | Phase 2 | 2025-07-25 | NCT07085156 | |
| Β-Thalassemia Treatment with KL003 Cell Injection | Transfusion-dependent Beta-Thalassemia | Recruiting | Phase 1 / Phase 2 | 2025-03-10 | NCT06280378 | |
| Allogeneic Hematopoietic Stem Cell Transplantation Cohort Study | Allogeneic Hematopoietic Stem Cell Transplantation | Recruiting | Not stated | 2024-11-27 | NCT06708130 | |
| Boost Irradiation to the Supraclavicular Area Among High Risk cN3c Breast Cancer Patients | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 2 | 2024-05-08 | NCT06404697 | |
| Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, digestive system disorder, digestive system neoplasm, gastric cancer, gastric neoplasm, neoplasm, stomach disorder | Recruiting | Phase 3 | 2024-01-26 | NCT05918094 | |
| Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Recruiting | Phase 3 | 2023-03-14 | NCT05768503 |